EcoDrugPlus

5-Hydroxytryptamine Receptor 2c

Ensembl ID : ENSG00000147246
Gene: HTR2C
Gene Synonyms: 5-HT2C,5HTR2C,HTR1C
34 APIs:
8 Enzyme and pathways 8 Cross references
227 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

5-Hydroxytryptamine Receptor 3a

Ensembl ID : ENSG00000166736
Gene: HTR3A
Gene Synonyms: 5-HT3A,5-HT3R,HTR3
19 APIs:
3 Enzyme and pathways 7 Cross references
207 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

5-Hydroxytryptamine Receptor 3b

Ensembl ID : ENSG00000149305
Gene: HTR3B
Gene Synonyms: 5-HT3B
10 APIs:
3 Enzyme and pathways 7 Cross references
175 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

5-Hydroxytryptamine Receptor 3c

Ensembl ID : ENSG00000178084
Gene: HTR3C
Gene Synonyms:
10 APIs:
3 Enzyme and pathways 7 Cross references
33 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

5-Hydroxytryptamine Receptor 3d

Ensembl ID : ENSG00000186090
Gene: HTR3D
Gene Synonyms:
10 APIs:
3 Enzyme and pathways 7 Cross references
57 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

5-Hydroxytryptamine Receptor 3e

Ensembl ID : ENSG00000186038
Gene: HTR3E
Gene Synonyms:
10 APIs:
3 Enzyme and pathways 7 Cross references
37 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

5-Hydroxytryptamine Receptor 4

Ensembl ID : ENSG00000164270
Gene: HTR4
Gene Synonyms: 5-HT4
19 APIs:
8 Enzyme and pathways 7 Cross references
201 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

5-Hydroxytryptamine Receptor 5a

Ensembl ID : ENSG00000157219
Gene: HTR5A
Gene Synonyms: 5-HT5A
3 APIs:
8 Enzyme and pathways 8 Cross references
216 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

5-Hydroxytryptamine Receptor 6

Ensembl ID : ENSG00000158748
Gene: HTR6
Gene Synonyms: 5-HT6,5-HT6R
7 APIs:
8 Enzyme and pathways 7 Cross references
115 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

5-Hydroxytryptamine Receptor 7

Ensembl ID : ENSG00000148680
Gene: HTR7
Gene Synonyms: 5-HT7
5 APIs:
10 Enzyme and pathways 7 Cross references
220 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

A-Raf Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSG00000078061
Gene: ARAF
Gene Synonyms: ARAF1
1 APIs:
20 Enzyme and pathways 7 Cross references
192 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Abl Proto-Oncogene 1, Non-Receptor Tyrosine Kinase

Ensembl ID : ENSG00000097007
Gene: ABL1
Gene Synonyms: ABL,C-ABL,JTK7,P150
21 APIs:
43 Enzyme and pathways 9 Cross references
204 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).